Folotyn for Non-Hodgkin's Lymphoma Mastic NY

The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday. The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

Local Companies

Bradley David Cohen
(631) 581-4400
111 Carleton Ave
Islip Terrace, NY
LAURA HOGAN, MD
(631) 638-1000
3 Edmund D Pellegrino Road
Stony Brook, NY
Marilyn A Mc Laughlin, MD
631-727-7100
36 Osprey Ave
Riverhead, NY
Edward Scott Valentine, MD
631-444-2200
15th Fl Rm 040,
Stony Brook, NY
Dr.Jeffrey Vacirca
(631) 751-3000
235 N Belle Mead Ave
East Setauket, NY
Vijay Shah
(718) 204-0414
444 W Main St
Patchogue, NY
MARISA SIEBEL, MD
(631) 444-2540
University Hospital, L5
Stony Brook, NY
DEVINA PRAKASH, MD
(631) 444-2585
University Hospital
Stony Brook, NY
Regina Lottie Jablonski, MD
631-751-3000
235 N Belle Mead Rd
East Setauket, NY
Lisa Cupit, MD
631-444-2059
T-15 Rm 040,
Stony Brook, NY
Data Provided by:
      

Provided By:

FRIDAY, Sept. 25 (HealthDay News) -- The drug Folotyn (pralatrexate) has been approved to treat Peripheral T-cell Lymphoma (PTCL), an often aggressive form of non-Hodgkin's lymphoma, the U.S. Food and Drug Administration said Friday.

The drug, given accelerated approval because it treats an unmet medical need, was sanctioned for people whose disease has returned or hasn't responded to other types of chemotherapy, the agency said in a news release.

PTCL strikes fewer than 9,500 people each year in the United States, the FDA said. The disease affects a type of white blood cell, called a T-cell, involved in the body's disease-fighting immune system.

Approval of Folotyn was based on clinical data showing it reduced tumor size in 27 percent of 109 people with PTCL who were studied. The most common adverse reactions included sores of the lips, mouth and digestive tract, low white blood cell counts, fever, nausea and fatigue.

Since the drug can harm a fetus, women taking Folotyn should avoid becoming pregnant, the FDA said. Anyone taking the drug should also take folate and vitamin B12 supplements to help reduce irritation of the mucous membranes.

Folotyn is produced by Colorado-based Allos Therapeutics, which is required to conduct additional studies of tumor shrinkage and life expectancy, the agency said.

More information

The FDA has more about this drug.

Copyright © 2009 ScoutNews, LLC. All rights reserved.

Read Article at HealthDay.com

Related Articles
- Donor Stem-Cell Transplant for Acute Myeloid Leukemia Mastic NY
For most patients with acute myeloid leukemia (AML) who come out of remission, donor stem cells appear to offer the best shot at survival, a new analysis shows.
- Green Tea and Hematologic Malignancies Mastic NY